全文获取类型
收费全文 | 486篇 |
免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 15篇 |
基础医学 | 31篇 |
临床医学 | 26篇 |
内科学 | 267篇 |
皮肤病学 | 4篇 |
神经病学 | 20篇 |
外科学 | 19篇 |
预防医学 | 21篇 |
眼科学 | 11篇 |
药学 | 7篇 |
肿瘤学 | 86篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 3篇 |
2017年 | 9篇 |
2016年 | 10篇 |
2015年 | 12篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 37篇 |
2010年 | 11篇 |
2009年 | 7篇 |
2008年 | 15篇 |
2007年 | 22篇 |
2006年 | 17篇 |
2005年 | 20篇 |
2004年 | 24篇 |
2003年 | 18篇 |
2002年 | 26篇 |
2001年 | 16篇 |
2000年 | 21篇 |
1999年 | 23篇 |
1998年 | 16篇 |
1997年 | 10篇 |
1996年 | 2篇 |
1995年 | 8篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 15篇 |
1991年 | 8篇 |
1990年 | 8篇 |
1989年 | 10篇 |
1988年 | 12篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 10篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1979年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1903年 | 1篇 |
1898年 | 1篇 |
1882年 | 1篇 |
1879年 | 1篇 |
排序方式: 共有508条查询结果,搜索用时 15 毫秒
1.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
2.
Bei den akuten myeloischen Leuk?mien (AML) handelt es sich um heterogene, maligne Erkrankungen des h?matopoetischen Systems,
denen die maligne Transformation einer h?matopoetischen Vorl?uferzelle zugrunde liegt [9]. Folge dieser Transformation ist
ein Verlust oder die Einschr?nkung des Differenzierungspotentials der Zellen mit einem Ausreifungsstop auf einem frühen Stadium
der Myelopoese. Bei erhaltener Proliferationskapazit?t kommt es zur klonalen Expansion der malignen Zellen mit sukzessiver
„Verdr?ngung” der normalen H?matopoese, an deren Folgen der Patient unbehandelt innerhalb weniger Wochen verstirbt. Haupttodesursachen
sind Blutungen und /oder Infektionen. 相似文献
3.
A. Ganser B. Völkers P. Scigalla D. Hoelzer 《Journal of molecular medicine (Berlin, Germany)》1988,66(6):236-240
Summary Recombinant human erythropoietin (rhEpo), now available, might become increasingly more important for clinical use, e.g., in the treatment of anemia of chronic renal failure. As a prerequisite of clinical trials, we analyzed the stimulatory and suppressive effects of rhEpo on human hemopoiesis by adding rhEpo to in vitro cultures of nonadherent low-density bone marrow cells obtained from normal persons and from patients undergoing hemodialysis for chronic renal failure. rhEpo was shown to be an effective stimulus for erythroid and multilineage colony formation. The dose-response curve was similar for erythroid progenitors BFU-E from normal controls and patients with chronic renal failure. rhEpo had no effect on megakaryocytic colony formation nor on the megakaryocytic differentiation of multilineage stem cells. Because of a good stimulatory activity on erythroid and multilineage stem cells and lack of toxic effects, rhEpo might be useful in the treatment of certain kinds of anemia.Abbreviations BFU-E
burst-forming unit-erythroid
- CFU-E
colony forming unit-erythroid
- CFU-GEMM
CFU-granulocyte, erythrocyte, macrophage, megakaryocyte
- CFU-GM
CFU-granulocyte, macrophage
- CFU-Mk
CFU-megakaryocyte
- IMDM
Iscove's modified Dulbecco's medium
- Mo-CM
Mo-cell line conditioned medium
- rhEpo
recombinant human erythropoietin 相似文献
4.
5.
Michael G Kiehl Ludwig Kraut Rainer Schwerdtfeger Bernd Hertenstein Mats Remberger Nicolaus Kroeger Mathias Stelljes Martin Bornhaeuser Hans Martin Christoph Scheid Arnold Ganser Axel R Zander Joachim Kienast Gerhard Ehninger Dieter Hoelzer Volker Diehl Axel A Fauser Olle Ringden 《Journal of clinical oncology》2004,22(14):2816-2825
PURPOSE: The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors. PATIENTS AND METHODS: The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen-identical related (n = 103), or matched unrelated (n = 118) donor. RESULTS: Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P =.014) or who relapsed (P <.001). We observed a clear trend toward improved survival in favor of B-lineage ALL patients compared with T-lineage ALL patients (P =.052), and Philadelphia chromosome-positive patients had no poorer outcome than Philadelphia chromosome-negative patients. Total-body irradiation-based conditioning improved DFS in comparison with busulfan (P =.041). CONCLUSION: Myeloablative matched related or matched unrelated allogeneic hematopoietic stem-cell transplantation in ALL patients should be performed in first CR. 相似文献
6.
G Buesche M Freund R Hehlmann A Georgii A Ganser H Hecker H Heimpel C Fonatsch B Heinze M Pfirrmann S Holgado A Schmeil A Tobler J Hasford T Buhr H-H Kreipe 《Leukemia》2004,18(9):1460-1467
Bone marrow fibrosis (MF) has been shown to indicate therapy failure in Ph(+) chronic myeloid leukemia (CML). However, the results on the development of MF during interferon-alpha therapy of CML are controversial. The significance of the interferon dose has not been considered as yet. In total, 627 bone marrow biopsies taken prospectively from 200 patients with CML recruited in two studies using different doses of interferon-alpha +/- low-dose cytosine arabinoside were examined for MF before and during therapy. The results showed that the risk of MF depended significantly on the interferon-alpha dose applied (P<0.000005). MF progressed during low-dose therapy (3 x 5 x 10(6) IU/week), but was prevented from progression when applying high dose (5 x 10(6) IU/m(2)/per day). MF disappeared when high-dose interferon-alpha was combined with low-dose cytosine arabinoside (P<0.000005). The risk of death markedly increased when MF occurred or progressed (P<0.0009), independent of all other prognostic factors evaluated including the cytogenetic response. In conclusion, the effectiveness of interferon-alpha on MF depends on the treatment intensity. MF reverses when combining high-dose interferon-alpha with low-dose cytosine arabinoside, but progresses when applying low-dose interferon-alpha. MF appears to be a significant early indicator of ineffective therapy in CML. 相似文献
7.
8.
Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). 总被引:5,自引:0,他引:5
The important cell cycle regulatory gene p15(INK4b) has been shown to be inactivated in acute myeloid leukemia and myelodysplastic syndrome. Little is known about the expression and epigenetic modification of this gene in chronic myelomonocytic leukemia (CMML) that belongs to the myelodysplastic/myeloproliferative disorders (MDS/MPD) with a high proportion of blastic transformation. Analysis of bone marrow trephines in a series of 33 CMML cases showed an aberrant p15(INK4b) gene methylation in up to 58% of cases. Methylation was analyzed employing different methylation-specific PCR and genomic sequencing protocols. It turned out to be spread over a broad area of the 5' region and exhibited substantial heterogeneity between cases and even in individual patients. The degree of aberrant methylation was correlated with a reduced mRNA as well as reduced protein expression, and was associated with a higher expression of DNA methyltransferase DNMT 3A. We conclude that aberrant gene methylation is a frequent event in CMML that might contribute to the pathogenesis of this MDS/MPD. 相似文献
9.
Effect of intensified chemotherapy on the pluripotent haematopoietic progenitor cells CFU-GEMM in adult acute lymphoblastic leukaemia 总被引:2,自引:0,他引:2
In order to analyse the short-term and long-term effects of intensified induction chemotherapy, the frequency, cellular composition and proliferative state of the pluripotent haemopoietic progenitor cells CFU-GEMM was investigated in a total of 35 patients with acute lymphoblastic or acute undifferentiated leukaemia at diagnosis, as well as during and after therapy. At diagnosis, the number of CFU-GEMM/ml bone marrow aspirate was significantly reduced to 12.1 (95% confidence interval 2.1-70) as compared to healthy controls (50.4/ml; 95% confidence interval 66-3846/ml). While immediately after the end of induction therapy, the respective values for CFU-GEMM were still decreased (30.4/ml; 95% confidence interval 8.4-108); values not significantly different from normal were reached within the following 4 weeks. During and after cessation of maintenance therapy again no significant deviation from normal values was observed. Immunological analysis of single colonies revealed that during the early phase after remission induction only 60 +/- 7% of mixed colonies contained megakaryocytic cells (normal 86 +/- 3%; P less than 0.01) while normal values were found during and after maintenance therapy. Cell cycle analysis disclosed highly increased proliferative activity of pluripotent progenitor cells during marrow regeneration after induction therapy as well as during maintenance therapy, but a return to the resting state after cessation of maintenance therapy. It is concluded that this intensive chemotherapy regimen does not result in any apparent long-term damage to the pluripotent haemopoietic progenitor cells. 相似文献
10.
Effect of recombinant interferons alpha and gamma on human bone marrow- derived megakaryocytic progenitor cells 总被引:4,自引:3,他引:4
Interferons (IFNs) have been shown to suppress the proliferation of human pluripotent hematopoietic progenitor cells, CFU-GEMM, and committed erythroid (BFU-E, CFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. However, no information is yet available concerning the effect of IFNs on human megakaryocytic progenitor cells CFU-Mk. Furthermore the mechanisms underlying the inhibitory activity of IFNs are still controversial. Therefore highly purified recombinant IFN preparations, rIFN-alpha and rIFN-gamma, were assessed for their influence on in vitro growth of human bone marrow-derived CFU-Mk as well as CFU-GEMM. In addition, the role of hematopoietic accessory cells, that is, adherent cells and T lymphocytes, in the mediation of the suppressive effect of rIFNs was examined. When added to unseparated bone marrow cells, both rIFN preparations significantly inhibited colony formation with 50% inhibition of CFU-Mk occurring at 22 U/mL for rIFN-alpha and 59 U/mL for rIFN-gamma, while 50% inhibition of CFU-GEMM occurred at 59 U/mL for rIFN-alpha and 101 U/mL for rIFN-gamma. The suppressive effect of rIFN-alpha and rIFN-gamma was selectively abolished by monoclonal antibodies (MoAbs) against rIFN-alpha and rIFN- gamma, thus confirming that the inhibitory activity was due to the rIFN preparations used. The antiproliferative effect of rIFN-alpha and rIFN- gamma on CFU-GEMM growth was not associated with a decrease in the percentage of mixed colonies containing megakaryocytic cells as assessed by use of the MoAb C17.28 against platelet glycoprotein IIIa. Removal of adherent cells and T lymphocytes from the target bone marrow cells had no influence on the suppressive effect of rIFN-alpha, whereas it significantly reduced the inhibitory effect of rIFN-gamma on the growth of megakaryocytic colonies and the other hematopoietic progenitors. The data indicate that (1) human megakaryocytopoiesis is markedly inhibited by rIFN-alpha and rIFN-gamma, and (2) the inhibitory effect of rIFN-alpha is due to a direct action on hematopoietic progenitor cells, whereas the effect of rIFN-gamma is mediated to a significant degree through accessory cell populations. 相似文献